{"id":757166,"date":"2023-05-10T07:31:51","date_gmt":"2023-05-10T11:31:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-reports-first-quarter-2023-financial-results-and-provides-business-update\/"},"modified":"2023-05-10T07:31:51","modified_gmt":"2023-05-10T11:31:51","slug":"immunocore-reports-first-quarter-2023-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunocore-reports-first-quarter-2023-financial-results-and-provides-business-update\/","title":{"rendered":"Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n Immunocore Reports <\/strong>
\n First Quarter <\/strong>
\n 202<\/strong>
\n 3 <\/strong>
\n Financial Results and Provides Business Update<\/strong>\n <\/p>\n

\n KIMMTRAK <\/em>
\n net <\/em>
\n revenues of \u00a3<\/em>
\n 42<\/em>
\n .<\/em>
\n 1<\/em>
\n million ($<\/em>
\n 52.<\/em>
\n 0<\/em>
\n million) in <\/em>
\n Q<\/em>
\n 1<\/em>
\n 202<\/em>
\n 3<\/em>
\n , with <\/em>
\n continued commercial expansion<\/em>\n <\/p>\n

\n Randomization started <\/em>
\n in Phase 2\/3 <\/em>
\n trial with <\/em>
\n KIMMTRAK <\/em>
\n in<\/em>
\n previously<\/em>
\n –<\/em>
\n treated<\/em>
\n ,<\/em>
\n advanced melanoma<\/em>\n <\/p>\n

\n Patients continue to enroll in monotherapy and combination arms of IMC-F106C (PRAME-HLA-A02) Phase 1\/2 trial<\/em>\n <\/p>\n

\n Enrolling people living with HIV <\/em>
\n in multiple <\/em>
\n ascending dose <\/em>
\n part<\/em>
\n of <\/em>
\n IMC-M113V Phase 1 trial <\/em>\n <\/p>\n

\n Cash<\/em>
\n and cash equivalents <\/em>
\n increased to <\/em>
\n \u00a3337 million ($417 million)<\/em>
\n as of\u00a0<\/em>
\n March<\/em>
\n \u00a031, 202<\/em>
\n 3<\/em>\n <\/p>\n

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 May 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the first quarter ended March 31, 2023, and provided a business update.<\/p>\n

\u201cIn the first year of launch, we have established KIMMTRAK as the most prescribed medicine for HLA-A*02:01 positive patients with mUM in the US, Germany and France,\u201d commented Ralph Torbay, Head of Commercial of Immunocore<\/strong>. \u201cWe continue to work with health authorities and healthcare professionals to bring KIMMTRAK to more patients with mUM around the world, with the goal of extending their lives.”<\/p>\n

\n First<\/strong>
\n Quarter <\/strong>
\n 202<\/strong>
\n 3<\/strong>
\n Highlights (including post-period)<\/strong>\n <\/p>\n

\n
\n KIMMTRAK\u00ae (<\/em>
\n <\/strong>
\n
\n tebentafusp-tebn<\/em>
\n <\/strong>
\n
\n )<\/em>
\n <\/strong>
\n
\n for metastatic uveal melanoma<\/em>
\n <\/strong>
\n
\n (<\/em>
\n <\/strong>
\n
\n mUM<\/em>
\n <\/strong>
\n
\n )<\/em>
\n <\/strong>\n <\/p>\n

KIMMTRAK is approved in over 30 countries globally and commercial expansion continues as we prepare to make the medicine available to even more patients. Total net product revenue (or \u201cnet sales\u201d) arising from the sale of KIMMTRAK (tebentafusp) was \u00a342.1 million (or $52.0 million) for the first quarter of 2023, of which \u00a329.5 million (or $36.5 million) was in the United States, \u00a312.3 million (or $15.2 million) in Europe, and \u00a30.2 million (or $0.2 million) in international regions.<\/p>\n

During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK. In addition, the majority of mUM patients in the U.S. were being treated with KIMMTRAK in the community setting.<\/p>\n

In France and Germany, an estimated 80% and 70%, respectively, of first line HLA-A*02:01 positive patients with mUM treated in the first quarter received KIMMTRAK. The Company launched KIMMTRAK in Austria and Israel in the first quarter and expects the commercial transition in Italy in the second quarter of this year. The Company expects to launch KIMMTRAK in four additional European countries by the end of 2023.<\/p>\n

In April, the Company presented data in HLA-A*02:01+ patients with mUM at the 2023 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated a correlation between early circulating tumor DNA (ctDNA) reduction and longer overall survival (OS) in the Phase 3 trial with KIMMTRAK (tebentafusp). ctDNA reduction by week 9 was observed in 88% of first-line mUM patients (Phase 3 trial) and 71% in previously treated patients (Phase 2 trial). ctDNA clearance was also higher in first-line patients (37%) compared to second-line patients (13%). In both trials, this reduction was associated with longer OS. The Company presented additional data with tebentafusp including a final analysis, at almost 4 years of follow-up, from the Phase 2 trial, tumor response in orbital lesions, and in vitro data assessing direct and indirect mechanisms of tumor control from TCR-CD3 bispecifics in melanoma.<\/p>\n

The Company had two abstracts accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL:<\/p>\n

Title: Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp<\/p>\n